Top 10 Pharmaceutical Companies in China in 2022 by Market Capitalization

Jiangsu Hengrui Medicine Co Ltd, BeiGene Ltd, Chongqing Zhifei Biological Products Co Ltd, Yunnan Baiyao Group Co Ltd, and Huadong Medicine Co Ltd are the top 5 pharma companies in China in 2023 by market capitalization (as of Mar 31, 2023). Comprehensively, the top 10 Pharma companies in China had a total market cap of $159,240 million (as of Mar 31, 2023), with Jiangsu Hengrui Medicine Co Ltd having the highest ($39,754 million), followed by BeiGene Ltd ($22,664 million), and Chongqing Zhifei Biological Products Co Ltd ($19,078 million), while Walvax Biotechnology Co Ltd is the lowest ($8,068 million). Jiangsu Hengrui Medicine Co Ltd is China’s leading pharma company by market cap (as of Mar 31, 2023). The company reported revenues of $4,016 million for the fiscal year ended December 2021 (FY2021), a decrease of 0.07% over FY2020. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. It employed 24,491 people. BeiGene Ltd is another leading pharma company in China by market cap (as of Mar 31, 2023). The company reported revenues of $1,416 million for the fiscal year ended December 2022 (FY2022), an increase of 20.4% over FY2021. The company specialized in the development and commercialization of immuno-oncology medicines to treat cancers. It offers BRUKINSA, a BTK (Bruton’s tyrosine kinase) inhibitor against mantle cell lymphoma (MCL). It employed 9,200 people.